858105-05-2

Upstream product

• 858104-50-4 (4-{(2R,3R)-1-(4-fluoro-phenyl)-3-[(RS)-2-(4-fluoro-phenyl)-2-oxoethylsulfanyl]-4-oxo-azetidin-2-yl}-phenoxy)-acetic acid 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 276884-77-6 tert-Butyl (4-formylphenoxy)acetate 
• 858104-46-8 tert-butyl (4-{(1R)-1-[(4-fluorophenyl)amino]-2-[(4-methoxybenzyl)thio]-3-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]propyl}phenoxy)acetate 
• 858104-49-1 (3R,4R)-1-(4-fluorophenyl)-3-[(4-fluorobenzoyl)methylthio]-4-[4-(t-butoxycarbonylmethoxy)phenyl]azetidin-2-one 
• 858104-48-0 (3R,4R)-1-(4-fluorophenyl)-3-[(3-nitropyridin-2-yl)dithio]-4-[4-(t-butoxycarbonylmethoxy)phenyl]azetidin-2-one 
• 858104-47-9 (3R,4R)-1-(4-fluorophenyl)-3-(4-methoxybenzylsulphanyl)-4-[4-(t-butoxycarbonylmethoxy)phenyl]azetidin-2-one 
• 858104-44-6 tert-butyl (4-{[(4-fluorophenyl)imino]methyl}phenoxy)acetate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 1387445-08-0 C₄₀H₄₀F₂N₂O₈S 
• 1387472-99-2 C₂₄H₂₆FNO₅S 
• 1387445-04-6 C₁₅H₁₉FO₄S 
• 1152629-06-5 ethyl 2-[2-(4-fluorophenyl)-2-oxoethyl]sulfanylacetate 
• 1387473-21-3 C₂₆H₂₁F₂NO₅S 

Downstream Products

• 858103-97-6 N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[2-(4-fluorophenyl)-2-oxoethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-L-asparagine 
• 858103-63-6 N-{[4-((2R,3R)-1-(4-fluorophenyl)-3-{[(2RS)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-3-methyl-D-valine 
• 858103-14-7 N-({4-[(2R,3R)-1-(4-fluorophenyl)-3-{[(2RS)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-D-valine 

Relevant academic research and scientific papers

Selection and development of a route for cholesterol absorption inhibitor AZD4121

The development of a synthetic route to the cholesterol absorption inhibitor AZD4121 is presented. Key steps are a highly enantioselective CBS reduction, a stereospecific Staudinger reaction, an amine/lithium chloride mediated ester hydrolysis, and a resolution of a 50:50 diastereomeric mixture by recrystallization. The synthesis was accomplished in 10 linear steps, and the overall yield, when compared with the lead optimization (LO) route, was improved from 1% to 20%. All purifications of intermediates through preparative HPLC or silica gel chromatography were avoided. This was possible since many of the intermediates along the route could be used as such in the next step until an intermediate with suitable crystalline properties could be identified and purified through crystallization.

NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS USEFUL FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS

The application relates to novel 2-azetidinone derivatives of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof . The compounds are cholesterol absorption inhibitors and are useful in the treatment of hyperlipidaemic conditions, including atherosclerosis, Alzheimers' disease and cholesterol associated tumours. The application also relates to pharmaceutical formulations comprising such compounds and to processes for their preparation.

DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY

Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.